Loading cancer entity…
Loading cancer entity…
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03158064 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials